SCHEMBL5448461

SCHEMBL5448461

C=CCNC(=S)Nc1sc2c(c1C(N)=O)CCCC2

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GAA P10253 5/20 1.00
ALDH1A1 P00352 10/20 0.63
MAPT P10636 6/20 0.63
KMT2A Q03164 5/20 0.63
MEN1 O00255 4/20 0.63
LMNA P02545 3/20 0.63
HPGD P15428 4/20 0.60
SMN1; SMN2 Q16637 3/20 0.60
NPC1 O15118 3/20 0.60
RAB9A P51151 3/20 0.60
FLT3 P36888 4/20 0.57
CYP1A2 P05177 1/20 0.57
CYP2C19 P33261 1/20 0.57
NPSR1 Q6W5P4 1/20 0.56
RXFP1 Q9HBX9 1/20 0.56
TSHR P16473 3/20 0.55
GFER P55789 1/20 0.55
L3MBTL1 Q9Y468 1/20 0.55
KDM4E B2RXH2 2/20 0.54
ALOX15 P16050 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8289828 0.78 FLT3 (0.67) GAAALDH1A1MAPTKMT2AMEN1
SCHEMBL8289841 0.77 HPGD (0.69) GAAALDH1A1MAPTKMT2AMEN1
SCHEMBL5451399 0.77 FLT3 (0.64) GAAALDH1A1MAPTKMT2AMEN1
SCHEMBL8290766 0.76 ALDH1A1 (0.68) GAAALDH1A1MAPTKMT2AMEN1
SCHEMBL5453598 0.75 FLT3 (0.62) GAAALDH1A1MAPTKMT2AMEN1
SCHEMBL3914847 0.74 FLT3 (1.00) ALDH1A1MAPTKMT2AMEN1LMNA
SCHEMBL5804129 0.73 KDM4E (0.75) GAAALDH1A1MAPTKMT2AMEN1
SCHEMBL3453042 0.73 FLT3 (0.75) GAAALDH1A1MAPTKMT2AMEN1
SCHEMBL5453467 0.73 FLT3 (1.00) GAAALDH1A1MAPTKMT2AMEN1
SCHEMBL4135422 0.73 HPGD (0.83) GAAALDH1A1MAPTKMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070275962-A1 Heterobicyclic Compounds as Pharmaceutically Active Agents GPC BIOTECH AG (DE) 2007-11-29 US claimed
EP-1670804-A2 HETEROBICYCLIC COMPOUNDS AS PHARMACEUTICALLY ACTIVE AGENTS GPC Biotech AG (DE) 2006-06-21 EP claimed
WO-2005023818-A2 HETEROBICYCLIC COMPOUNDS AS PHARMACEUTICALLY ACTIVE AGENTS GPC BIOTECH AG (DE) 2005-03-17 WO claimed
US-20070275962-A1 Heterobicyclic Compounds as Pharmaceutically Active Agents GPC BIOTECH AG (DE) 2007-11-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070275962-A1 Heterobicyclic Compounds as Pharmaceutically Active Agents TBCA, PARK7, NFATC1 GAA 540/4885ALDH1A1 1153/4885MAPT 21/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.